<DOC>
	<DOCNO>NCT02039505</DOCNO>
	<brief_summary>This study phase 3 , multicenter , randomize , double-blinded , placebo-controlled , parallel-group study examine efficacy , safety , pharmacokinetics MLN0002 ( Vedolizumab ) induction maintenance therapy Japanese patient moderately severely active ulcerative colitis .</brief_summary>
	<brief_title>Phase III Study MLN0002 ( 300 mg ) Treatment Ulcerative Colitis</brief_title>
	<detailed_description>This study Phase 3 , multicenter , randomize , double-blinded , placebo-controlled , parallel-group study examine efficacy , safety , pharmacokinetics intravenous Vedolizumab ( 300 mg ) infusion induction maintenance therapy Japanese patient moderately severely active ulcerative colitis/</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Patients age 15 80 year ( inclusive ) time consent 2 . Patients diagnosis total leftsided colitis establish base Revised Diagnostic Criteria Ulcerative Colitis issue Research Group Intractable Inflammatory Bowel Disease Designated Specified Disease Ministry Health , Labor Welfare Japan ( 2012 ) least 6 month start administration study drug . 3 . Patients moderately severely active ulcerative colitis determine baseline complete Mayo score 6 12 ( inclusive ) endoscopic subscore ≥2 4 . In case patient meet following criterion ; patient ≥8year history total leftsided colitis , patient age ≥ 50 year , patient firstdegree family history colon cancer , complication colon cancer dysplasia rule total colonoscopy start study drug administration ( Or result total colonoscopy perform within 1 year give consent available ) . 5 . Patients meet criterion treatment failure least one follow agent receive within previous 5 year period give consent . Corticosteroids Resistance Dependence Intolerance Immunomodulators ( azathioprine 6mercaptopurine ) Refractory Intolerance AntiTNFα antibody Inadequate response Loss response Intolerance 1 . Patients whose partial Mayo score decrease 3 point screen start study drug administration 2 . Patients evidence suspect abdominal abscess toxic megacolon 3 . Patients history subtotal total colectomy 4 . Patients ileostomy , colostomy , fistula , severe intestinal stenosis 5 . Patients start 5aminosalicylic acid oral drug probiotic treatment 30 mg/day less oral corticosteroid within 13 day initiation study drug administration . If drug use within 14 day initiation study drug administration , dosage must change use discontinue within 13 day initiation study drug administration 6 . Patients receive 5aminosalicylic acid corticosteroid enemas/suppositories , intravenous corticosteroid injection , 30 mg/day oral corticosteroid , medication diarrheapredominant irritable bowel syndrome , Chinese herbal medicine treatment ulcerative colitis ( e.g. , Daikenchuto ) within 13 day initiation study drug administration 7 . Patients receive antidiarrheal drug 4 day consecutively within 13 day initiation study drug administration antidiarrheal drug within 7 day initiation study drug administration 8 . Patients receive azathioprine 6mercaptopurine within 27 day initiation study drug administration . However , shall apply patient receive drug 83 day initiation study drug administration continue steady dose administration drug 27 day initiation study drug administration 9 . Patients receive cyclosporin , tacrolimus , methotrexate , tofacitinib study drug treatment ulcerative colitis within 27 day initiation study drug administration 10 . Patients receive adalimumab within 27 day initiation study drug administration biological drug adalimumab within 55 day initiation study drug administration . Topical administration ( intraocular implantation treatment agerelated maculopacy ) allow 11 . Patients receive live vaccination within 27 day initiation study drug administration 12 . Patients undergone intestinal resection within 27 day initiation study drug administration anticipate require intestinal resection study 13 . Patients receive leukocytapheresis granulocyte apheresis within 27 day initiation study drug administration 14 . Patients evidence adenomatous colonic polyp need remove start study drug administration 15 . Patients history complication colonic mucosal dysplasia</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>